دورية أكاديمية
Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States.
| العنوان: | Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States. |
|---|---|
| المؤلفون: | Bhatt NS; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Electronic address: nbhatt@fredhutch.org., Brazauskas R; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Biostatistics, Institute of Health and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin., Salit RB; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Syrjala K; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Bo-Subait S; Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis, Minnesota., Tecca H; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin., Badawy SM; Division of Hematology, Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois; Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois., Baker KS; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Beitinjaneh A; Division of Transplantation and Cellular Therapy, University of Miami, Miami, Florida., Bejanyan N; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida., Byrne M; Vanderbilt University Medical Center, Nashville, Tennessee., Dias A; Beth Israel Deaconess Medical Center, Boston, Massachusetts., Farhadfar N; Division of Hematology/Oncology, University of Florida College of Medicine, Gainesville, Florida., Freytes CO; Texas Transplant Institute, San Antonio, Texas., Ganguly S; Division of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, Kansas., Hashmi S; Department of Internal Medicine, Mayo Clinic, Minnesota; Department of Medicine, Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates., Hayashi RJ; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Washington University School of Medicine in St Louis, St Louis, Missouri., Hong S; Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio., Inamoto Y; Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan., Jamani K; Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada., Kasow KA; University of North Carolina, Chapel Hill, North Carolina., Khera N; Department of Hematology/Oncology, Mayo Clinic, Phoenix, Arizona., Krem MM; Markey Cancer Center, University of Kentucky College of Medicine, Lexington, Kentucky., Lazarus HM; University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio., Lee CJ; Utah Blood and Marrow Transplant Program at Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah., Lee S; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin., Majhail NS; Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio., Malone AK; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Marks DI; Adult Bone Marrow Transplant, University Hospitals Bristol NHS Trust, Bristol, United Kingdom., Mau LW; Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis, Minnesota., Mayo SJ; Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada., Muffly LS; Division of Blood and Marrow Transplantation, Stanford University, Stanford, California., Nathan S; Section of Bone Marrow Transplant and Cell Therapy, Rush University Medical Center, Chicago, Illinois., Nishihori T; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida., Page KM; Division of Pediatric Blood and Marrow Transplantation, Duke University Medical Center, Durham, North Carolina., Preussler J; Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis, Minnesota., Rangarajan HG; Department of Pediatric Hematology, Oncology, Blood and Marrow Transplantation, Nationwide Children's hospital, Columbus, Ohio., Rotz SJ; Department of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Cleveland Clinic Children's Hospital, Cleveland, Ohio., Salooja N; Imperial College London, London, United Kingdom., Savani BN; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Schears R; University of Central Florida, Department of Emergency Medicine, Orlando, Florida., Schechter-Finkelstein T; Hospital for Sick Children, Toronto, Ontario Canada., Schiller G; Hematological Malignancy/Stem Cell Transplant Program, David Geffen School of Medicine at UCLA, Los Angeles, California., Shah AJ; Division of Stem Cell Transplantation and Regenerative Medicine, Lucille Packard Children's Hospital, Stanford School of Medicine, Palo Alto, California., Sharma A; Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee., Wang T; Division of Transplantation and Cellular Therapy, University of Miami, Miami, Florida., Wirk B; Penn State Cancer Institute, Bone Marrow Transplant Program, Hershey, Pennsylvania., Battiwalla M; Sarah Cannon Blood Cancer Network, Nashville, Tennessee., Schoemans H; Department of Hematology, University Hospitals Leuven and KU Leuven, Leuven, Belgium., Hamilton B; Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio., Buchbinder D; Division of Pediatric Hematology, Children's Hospital of Orange County, Orange, California., Phelan R; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin., Shaw B; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin. |
| المصدر: | Transplantation and cellular therapy [Transplant Cell Ther] 2021 Aug; Vol. 27 (8), pp. 679.e1-679.e8. Date of Electronic Publication: 2021 Apr 22. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101774629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-6367 (Electronic) Linking ISSN: 26666367 NLM ISO Abbreviation: Transplant Cell Ther Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [New York] : Elsevier Inc., [2021]- |
| مواضيع طبية MeSH: | Hematopoietic Stem Cell Transplantation* , Return to Work*, Female ; Humans ; Neoplasm Recurrence, Local ; Survivors ; Transplantation, Homologous ; United States ; Young Adult |
| مستخلص: | Young adult (YA) survivors of allogeneic hematopoietic cell transplantation (HCT) are at risk for late psychosocial challenges, including the inability to return to work post-HCT. Work-related outcomes in this population remain understudied, however. We conducted this study to assess the post-HCT work status of survivors of allogeneic HCT who underwent HCT as YAs and to analyze the patient-, disease-, and HCT-related factors associated with their work status at 1 year post-HCT. Using Center for International Blood and Marrow Transplant Research data, we evaluated the post-HCT work status (full-time, part-time work, unemployed, or medical disability) of 1365 YA HCT survivors who underwent HCT between 2008 and 2015. Percentages of work status categories were reported at 4 time points: 6 months, 1 year, 2 years, and 3 years post-HCT. Percentages of post-HCT work status categories at the 1-year time point were also described in relation to survivors' pre-HCT work status categories. Factors associated with 1-year post-HCT work status (full-time or part-time work) were examined using logistic regression. From 6 months to 3 years post-HCT, the percentage of survivors working full-time increased from 18.3% to 50.7% and the percentage working part-time increased from 6.9% to 10.5%. Of patients in full-time work pre-HCT, 50% were unemployed or on medical disability at 1 year post-HCT. Female sex (odds ratio [OR], 0.55; 95% confidence interval [CI], 0.40 to 0.77), HCT Comorbidity Index score ≥3 (OR, 0.57; 95% CI, 0.39 to 0.82), pre-HCT unemployment (OR, 0.37; 95% CI, 0.24 to 0.56), medical disability (OR, 0.44; 95% CI, 0.28 to 0.70), development of grade III-IV acute graft-versus-host disease (OR, 0.52; 95% CI, 0.34 to 0.80), and relapse within 1 year post-HCT (OR, 0.34; 95% CI, 0.21 to 0.56) were associated with a lower likelihood of employment at 1 year post-HCT. Compared with myeloablative conditioning (MAC) with total body irradiation (TBI), MAC without TBI (OR, 1.71; 95% CI, 1.16 to 2.53) was associated with a greater likelihood of employment at 1 year post-HCT. Graduate school-level education (OR, 2.47; 95% CI, 1.49 to 4.10) was also associated with a greater likelihood of employment at 1 year post-HCT. Although the work status among YA HCT survivors continued to improve over time, a substantial subset became or remained unemployed or on medical disability. These findings underscore the need for effective interventions to support return to work in this population. (Copyright © 2021 The American Society for Transplantation and Cellular Therapy. All rights reserved.) |
| References: | Biol Blood Marrow Transplant. 2020 Aug;26(8):e177-e182. (PMID: 32438042) Bone Marrow Transplant. 2017 Oct;52(10):1436-1442. (PMID: 28650451) J Cancer Surviv. 2020 Apr;14(2):114-134. (PMID: 31858379) JAMA. 2010 Apr 28;303(16):1617-24. (PMID: 20424252) Psychooncology. 2018 Feb;27(2):532-538. (PMID: 28778113) J Cancer Surviv. 2010 Mar;4(1):33-44. (PMID: 19936935) Biol Blood Marrow Transplant. 2016 Sep;22(9):1690-1695. (PMID: 27220264) J Adolesc Young Adult Oncol. 2021 Apr;10(2):226-233. (PMID: 32746763) Support Care Cancer. 2011 Sep;19(9):1357-65. (PMID: 20661753) Blood. 2020 May 21;135(21):1847-1858. (PMID: 32243495) J Pediatr Hematol Oncol. 2019 Apr;41(3):233-237. (PMID: 29923857) Biol Blood Marrow Transplant. 2014 Sep;20(9):1375-81. (PMID: 24867778) Transplantation. 1974 Oct;18(4):295-304. (PMID: 4153799) J Cancer Surviv. 2017 Dec;11(6):765-781. (PMID: 28478587) Cancer. 2019 Jan 1;125(1):144-152. (PMID: 30368771) Cancer. 2019 Jun 1;125(11):1908-1917. (PMID: 30707763) Med Care. 2010 Nov;48(11):1015-25. (PMID: 20940653) Blood. 2011 Aug 4;118(5):1413-20. (PMID: 21652685) Biol Blood Marrow Transplant. 2018 Feb;24(2):228-241. (PMID: 28939455) J Clin Oncol. 2017 Jan 20;35(3):306-313. (PMID: 27870568) Bone Marrow Transplant. 2008 Dec;42(12):819-27. (PMID: 18711345) JAMA Oncol. 2016 Dec 1;2(12):1583-1589. (PMID: 27532508) Bone Marrow Transplant. 2014 Jun;49(6):836-42. (PMID: 24614841) J Adolesc Young Adult Oncol. 2017 Dec;6(4):551-559. (PMID: 28594579) Br J Haematol. 2001 Apr;113(1):194-201. (PMID: 11328302) Health Aff (Millwood). 2014 Jun;33(6):1024-31. (PMID: 24889952) Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1. (PMID: 25529383) J Adolesc Young Adult Oncol. 2018 Aug;7(4):445-452. (PMID: 29641360) Cancer. 2012 Dec 1;118(23):5964-72. (PMID: 23007632) J Psychosoc Oncol. 2011;29(4):394-414. (PMID: 21966725) JAMA. 2004 May 19;291(19):2335-43. (PMID: 15150205) J Clin Oncol. 2012 Jul 1;30(19):2393-400. (PMID: 22614977) Bone Marrow Transplant. 2016 Jun;51(6):786-92. (PMID: 26901709) |
| معلومات مُعتمدة: | R01 CA215134 United States CA NCI NIH HHS; U01 CA246659 United States CA NCI NIH HHS; U24 CA076518 United States CA NCI NIH HHS; UL1 TR001422 United States TR NCATS NIH HHS |
| فهرسة مساهمة: | Keywords: Hematopoietic cell transplantation; Quality of life; Return to work; Young adult |
| تواريخ الأحداث: | Date Created: 20210425 Date Completed: 20210802 Latest Revision: 20220802 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC8425287 |
| DOI: | 10.1016/j.jtct.2021.04.013 |
| PMID: | 33895402 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder كن أول من يترك تعليقا!